Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Biomarin Pharmaceutical's interest expense for the
three
months ended in Sep. 2021 was $ -4 Mil.
Its interest expense for the trailing twelve months (TTM) ended in Sep. 2021 was $-16 Mil.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Biomarin Pharmaceutical's Operating Income for the
three
months ended in Sep. 2021 was $ -53 Mil. Biomarin Pharmaceutical's Interest Expense for the
three
months ended in Sep. 2021 was $ -4 Mil.
Biomarin Pharmaceutical did not have earnings to cover the interest expense.
The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Biomarin Pharmaceutical Interest Expense Calculation
Interest Expense is the amount reported by a company or individual as an expense for borrowed money.
Interest Expense for the trailing twelve months (TTM) ended in Sep. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $-16 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biomarin Pharmaceutical (NAS:BMRN) Interest Expense Explanation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Biomarin Pharmaceutical's Interest Expense for the
three
months ended in Sep. 2021 was $-4 Mil. Its
Operating Income
for the
three
months ended in Sep. 2021 was $-53 Mil. And its Long-Term Debt & Capital Lease Obligation for the
three
months ended in Sep. 2021 was $1,078 Mil.
Biomarin Pharmaceutical's Interest Coverage for the quarter that ended in Sep. 2021 is calculated as
| Biomarin Pharmaceutical did not have earnings to cover the interest expense. |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's financial strength is.
Biomarin Pharmaceutical Business Description
Traded in Other Exchanges
Address
770 Lindaro Street, San Rafael, CA, USA, 94901
BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). BioMarin's Roctavian (hemophilia A gene therapy) and vosoritide (treatment for achondroplasia) are poised to potentially launch in the 2021-22 timeframe.
Executives
| Ajer Jeffrey Robert |
officer: EVP, Chief Commercial Officer |
C/O BIOMARIN PHARMACEUTICAL INC. 105 DIGITAL DRIVE NOVATO CA 94949 |
| Heron Elaine J |
director |
6 STONEGATE RD PONTOLA VALLEY CA 94028 |
| Pyott David E I |
director |
C/O ALLERGAN 2525 DUPONT DRIVE IRVINE CA 92612 |
| Grey Michael G |
director |
C/O SGX PHARMACEUTICALS, INC. 10505 ROSELLE STREET SAN DIEGO CA 92121 |
| Fuchs Henry J |
officer: President, Worldwide R&D |
C/O BIOMARIN PHARMACEUTICAL INC. 105 DIGITAL DRIVE NOVATO CA 94949 |
| Acosta Andrea |
officer: GVP, Chief Accouning Officer |
C/O BIOMARIN PHARMACEUTICAL INC. 770 LINDARO ST SAN RAFAEL CA 94901 |
| Dere Willard H |
director |
ONE AMGEN CENTER DRIVE THOUSAND OAKS CA 91320-1799 |
| Lawlis V Bryan |
director |
PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"> Ownership Information: LAWLIS V BRYAN a.header:link {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:visited {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:hover {color: #191970;} |
| Anderson Elizabeth M |
director |
10 FINDERNE AVENUE BUILDING 10 BRIDGEWATER NJ 08807 |
| Hombach Robert J. |
director |
C/O BAXALTA INCORPORATED 1200 LAKESIDE DRIVE BANNOCKBURN IL 60015 |
| Slamon Dennis |
director |
770 LINDARO STREET SAN RAFAEL CA 94901 |
| Meier Richard A |
director |
1700 E ST ANDREW PLACE SANTA ANA CA 92705 |
| Bienaime Jean Jacques |
director, officer: Chief Executive Officer |
925 PAGE MILL ROAD PALO ALTO CA 94304 |
| Guyer Charles Greg |
officer: EVP, Chief Technical Officer |
C/O BIOMARIN PHARMACEUTICAL INC. 770 LINDARO ST. SAN RAFAEL CA 94901 |
| Mueller Brian |
officer: EVP, Chief Financial Officer |
C/O BIOMARIN PHARMACEUTICAL INC. 105 DIGITAL DRIVE NOVATO CA 94949 |
Biomarin Pharmaceutical Headlines
By Seekingalpha 2021-06-02
By Seekingalpha 2021-02-26
By Seekingalpha 2021-07-28
My Portfolios
Create New Portfolio
Portfolio Contest
My Gurus
Personalize
My Gurus
1.88(2.23%) Volume: 1,227,083 2:08AM EST
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
NAS:BMRN has been successfully added to your 
